Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.7552W HIGH $52.93
Volume
689.24 K
Value Traded
12.37 M
Short % Float
10.59%
Days to Cover
11.8
-6.23%Week
-17.64%1 Month
-34.37%3 Month
-18.38%6 Month
+109.56%5 Year
+109.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.32 B
EPS (TTM)
-2.86
P/E Ratio
-
Ent. Value
885.24 M
Total Shares
47.98 M
Float Shares
28.81 M
Insiders
39.96%
Institutions
75.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RAPP Catalyst Timeline
Dated clinical, regulatory and corporate events for Rapport Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rapport Therapeutics, Inc.
117Total events
23Upcoming
29Tier-1 (high impact)
2024 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Secondary Endpoint DataRAP-219Clinical Data
Statistically significant CGI-BP mania severity improvement at Week 3
bipolar maniasource ↗
▲Topline ReadoutRAP-219Clinical Data
Positive Phase 2 topline results in acute bipolar mania
bipolar maniasource ↗
▲Safety Data UpdateRAP-219Clinical Data
RAP-219 well tolerated over 3-week treatment period
bipolar maniasource ↗
▲Primary Endpoint MetRAP-219Clinical Data
Phase 2 met primary YMRS endpoint in bipolar mania
bipolar maniasource ↗
▲NMPA INDRAP-219Ex-US Regulatory
NMPA approved IND for RAP-219 Phase 3 trials in FOS
focal onset seizuressource ↗
▲PK PD DataRAP-219Clinical Data
RAP-219 half-life estimated at 22 days, increased from 14 days
●Enrollment UpdateRAP-219Trial
FOCUS 1 and FOCUS 2 trials enrolling patients
focal onset seizuressource ↗
▲Trial InitiationRAP-219Trial
Open-label long-term safety trial initiated
focal onset seizuressource ↗
◆Oral PresentationRAP-219Presentation
Podium presentation of Phase 2a treatment follow-up data for RAP-219 in focal onset seizures at AAN 2026
focal onset seizuressource ↗
▲Late-BreakerRAP-219Presentation
Late-breaker podium presentation of Phase 2a follow-up period results at AAN 2026
focal onset seizuressource ↗
▲Trial InitiationRAP-219Trial
Open-label long-term safety trial initiated; majority of Phase 2 patients enrolled
focal onset seizuressource ↗
▲Full ResultsRAP-219Clinical Data
Phase 2a follow-up period data presented at AAN showing sustained seizure reduction
focal onset seizuressource ↗
▲Oral PresentationRAP-219Presentation
Presented 8-week follow-up data from Phase 2a trial at AAN Annual Meeting
focal onset seizuressource ↗
▲Partnership / LicenseRAP-219Corporate
Strategic collaboration with Tenacia for development and commercialization in Greater China
focal onset seizures, bipolar maniasource ↗
◆Oral PresentationPresentation
TD Cowen 46th Annual Healthcare Conference presentation and fireside chat
▲Partnership / LicenseRAP-219Corporate
Strategic collaboration and license agreement with Tenacia Biotechnology for Greater China
▼Program DiscontinuationRAP-219Corporate
Deferral of investment in RAP-219 DPNP program
diabetic peripheral neuropathic painsource ↗
▲Clinical Hold LiftedRAP-219IND
FDA removed clinical hold on Phase 2 DPNP trial
diabetic peripheral neuropathic painsource ↗
▲Pipeline PrioritizationCorporate
Prioritization of α6β4 program in chronic pain and migraine
chronic pain and migrainesource ↗
◆Timing GuidanceRAP-219Presentation
Update on next steps for Phase 2 diabetic peripheral neuropathic pain trial expected in Q1 2026
diabetic peripheral neuropathic painsource ↗
▲Trial InitiationRAP-219Trial
Open-label long-term safety trial initiated
focal onset seizuressource ↗
▲Primary Endpoint MetRAP-219Clinical Data
Phase 2a trial met primary long episode endpoints with high statistical significance
focal onset seizuressource ↗
◆Poster PresentationRAP-219Presentation
Presentation of Phase 2a trial results and new efficacy analysis of RAP-219 in focal onset seizures at AES 2025
focal onset seizuressource ↗
▲Oral PresentationRAP-219Presentation
New data and post hoc analysis presented at AES 2025 Annual Meeting
drug-resistant focal onset seizuressource ↗
▲Full ResultsRAP-219Clinical Data
New data and post hoc analysis of RAP-219 Phase 2a presented at AES 2025
drug-resistant focal onset seizuressource ↗
▲End Of Phase 2 MeetingRAP-219FDA Meeting
End-of-Phase 2 meeting with FDA in December 2025
focal onset seizuressource ↗
▲Clinical Hold LiftedRAP-219IND
FDA removed clinical hold on RAP-219 DPNP IND
diabetic peripheral neuropathic painsource ↗
◆End Of Phase 2 MeetingRAP-219FDA Meeting
End-of-Phase 2 meeting with FDA planned this quarter
drug-resistant focal onset seizuressource ↗
◆Trial InitiationRAP-219Trial
Initiation of open-label long-term safety trial expected
drug-resistant focal onset seizuressource ↗
◆Oral PresentationPresentation
Rapport management to participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
▼Equity OfferingCorporate
Pricing of underwritten public offering of 9,615,385 shares at $26.00 per share
▲Primary Endpoint MetRAP-219Clinical Data
Phase 2a trial met primary endpoint with statistically significant reduction in long episodes
drug-resistant focal onset seizuressource ↗
◆Oral PresentationRAP-219Presentation
Conference call and webcast to discuss Phase 2a data
drug-resistant focal onset seizuressource ↗
▲Topline ReadoutRAP-219Clinical Data
Topline results from Phase 2a FOS trial announced
drug-resistant focal onset seizuressource ↗
▲Enrollment CompleteRAP-219Trial
Phase 2a trial fully enrolled
drug-resistant focal onset seizuressource ↗
◆Topline ReadoutRAP-219Clinical Data
Topline Phase 2a results in refractory focal epilepsy expected in Q3 2025
refractory focal epilepsysource ↗
Past FDA Catalysts and PDUFA Decisions
How RAPP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-20 | RAP-219 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 27%
Micro Cap(rank 178 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RAP-219 Small moleculeNCT07563881 | Focal Seizure | Phase 3 | RECRUITING | 645 | Sep 1, 2029 | ||||||
| RAP-219 Small moleculeNCT07219407 | Focal Epilepsy | Phase 2 | RECRUITING | 30 | Feb 3, 2028 | ||||||
| RAP-219 Small moleculeNCT07046494 | Bipolar 1 Disorder | Phase 2 | COMPLETED | 253 | Sep 24, 2026 | ||||||
| RAP-219 Small moleculeCompletedNCT06377930 | Focal Onset Seizures | Phase 2 | COMPLETED | 30 | Sep 26, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every RAPP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RAP-219 | acute bipolar mania | Phase 2 | 2026-10-20 | YMRS improvement: 3.1 points; p value YMRS: 0.045; mean reduction YMRS: 15.4 points; CGI BP improvement: 0.4 points; p value CGI BP: 0.024Read More | Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar ManiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sanchez RamiroDirector | Buy | 3,600 3,600 held | $27.35 | 10/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RAPP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 4.1 % (78.3 %) | 79.36 M | 1.90 M |
RAPP Institutional Ownership Trends
RAPP Short Interest
Shares sold short, counted twice a month.
10.59%
Short % of Float
of tradable shares sold short
3.1M
Shares Sold Short
-4.5% vs prior count
11.8 Very high
Days to Cover
trading days of normal volume to buy every short share back
259.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RAPP ranks across every disease it competes in
Competitive Position is a premium feature
See how RAPP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRAPP News
RAPP▼ -13.1%today
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Rapport Therapeutics announced public offerings of $200 million in common stock and $150 million in convertible notes. The company also plans a concurrent private placement. Proceeds will fund clinical trials for RAP-219 and general corporate purposes. The offerings are subject to market conditions and underwriter agreements.
Read more →RAPPRapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for treating acute bipolar mania. The trial demonstrated statistically significant improvements in manic symptoms, with a notable reduction in the Young Mania Rating Scale (YMRS) total score. RAP-219 was well-tolerated, and the company plans to advance to Phase 3 trials in 2027.
Read more →RAPPRapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The events include a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026, and another at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. These engagements highlight the company's commitment to advancing its precision medicine pipeline for neurological and psychiatric disorders.
Read more →RAPPRapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Rapport Therapeutics will host a virtual KOL event on September 22, 2026, focusing on the challenges in treating bipolar mania and the potential of RAP-219. Experts will discuss the limitations of current treatments and the ongoing Phase 2 trial of RAP-219, which aims to provide a new therapeutic option. Topline data from the trial is expected in October 2026.
Read more →RAPPRapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported its financial results for Q2 2026, highlighting the initiation of the Phase 3 program for RAP-219 targeting focal onset seizures. The company also noted progress in its bipolar mania trial and other pipeline developments. Despite a significant net loss, Rapport maintains a strong cash position, expected to support operations until 2029.
Read more →RAPPRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Read more →RAPP▲ +7.7%on this news
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported positive Phase 2a data for RAP-219, showing a 90% median reduction in focal onset seizures. The company anticipates topline results for its bipolar mania trial in Q4 2026, ahead of previous guidance. With a strong cash position of $476.8 million, Rapport is well-positioned for continued development, including a Phase 3 program in focal onset seizures set to begin in Q2 2026.
Read more →RAPPRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics recently presented encouraging follow-up results from its Phase 2a trial of RAP-219 for focal onset seizures at the American Academy of Neurology Annual Meeting. The data indicated a significant median reduction in clinical seizures, including a 90% reduction in the first four weeks post-treatment. RAP-219 exhibited a long half-life of approximately 22 days, allowing for maintained therapeutic levels. The drug was generally well tolerated throughout the trial, setting the stage for upcoming pivotal Phase 3 studies slated to begin in the second quarter of 2026.
Read more →RAPPRapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics will present new follow-up data from its Phase 2a trial of RAP-219 for focal onset seizures at the 2026 American Academy of Neurology Annual Meeting. The presentation will highlight the efficacy and tolerability of RAP-219, a potential first-in-class negative allosteric modulator. The meeting is scheduled for April 18-22, 2026, in Chicago.
Read more →RAPPRapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics reported positive financial results for Q4 and full year 2025, highlighting robust Phase 2a trial outcomes for its lead product RAP-219 in focal onset seizures. The company plans to initiate a Phase 3 program for RAP-219 in mid-2026 and has expanded its epilepsy portfolio to include primary generalized tonic-clonic seizures. Despite a net loss increase for the year, Rapport remains financially strong with substantial cash reserves expected to sustain operations until 2029. A strategic collaboration with Tenacia Biotechnology aims to boost RAP-219 development efforts in Greater China.
Read more →RAPPRapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics has entered a strategic collaboration with Tenacia Biotechnology for the development and commercialization of RAP-219 in Greater China. Tenacia will handle the drug's development in regions including mainland China, Hong Kong, Macau, and Taiwan, while Rapport retains global rights. The partnership includes a $20 million upfront payment and potential milestone payments totaling up to $308 million.
Read more →RAPPRapport Therapeutics to Participate in Upcoming March 2026 Investor Conferences
Rapport Therapeutics, a clinical-stage biotechnology firm, has announced its participation in several investor conferences in March 2026. These events include presentations and fireside chats at notable conferences in Boston and Miami. The company focuses on developing small molecule precision medicines for neurological and psychiatric disorders, highlighting its innovative RAP technology platform.
Read more →RAPP▲ +8.9%on this news
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Rapport Therapeutics will start Phase 3 trials for RAP-219 in focal onset seizures in the second quarter of 2026. The company also plans to launch a Phase 3 study for primary generalized tonic-clonic seizures in the first half of 2027. These moves expand its epilepsy portfolio based on positive Phase 2a data. The firm holds $513.0 million in cash to support operations through late 2029.
Read more →RAPPRapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Rapport Therapeutics announced promising post hoc analysis results for RAP-219, demonstrating its early efficacy and consistent response in patients with drug-resistant focal onset seizures. The Phase 2a trial showed a significant reduction in seizure frequency and improvements in patient-reported outcomes. The company plans to advance RAP-219 into pivotal Phase 3 trials following a meeting with the FDA.
Read more →RAPPRapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Rapport Therapeutics announced it will present new Phase 2a data for RAP-219, targeting focal onset seizures, at the 2025 American Epilepsy Society Annual Meeting. The presentation will include efficacy analysis and safety data, highlighting RAP-219's potential as a novel treatment. The event is scheduled for December 5-9, 2025, in Atlanta.
Read more →RAPPRapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported a net loss of $26.9 million for the third quarter of 2025. The company ended the period with $513.0 million in cash and short-term investments. This balance is sufficient to fund operations through the second half of 2029. The firm also announced positive Phase 2a results for its epilepsy drug RAP-219.
Read more →RAPPRapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics will participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, known for its precision medicine approach, is developing RAP-219 for conditions like drug-resistant focal onset seizures and bipolar mania. The event will feature a fireside chat accessible via the company's website.
Read more →RAPP▼ -20.1%on this newsshared move
Rapport Announces Pricing of Public Offering of Common Stock
Rapport Therapeutics has announced the pricing of a public offering of 9,615,385 shares of common stock at $26.00 per share, aiming to raise around $250 million. The offering is set to close on September 11, 2025, pending customary conditions. Rapport is focused on developing precision medicines for neurological and psychiatric disorders.
Read more →About Rapport Therapeutics, Inc.
Headquarters99 HIGH STREET, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next RAPP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime